Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenue of approximately RMB 13,087,071,000, a decrease of 1.1% compared to RMB 13,229,453,000 in the previous year[4] - The net profit attributable to the company's owners was approximately RMB 2,066,668,000, representing a growth of 3.2% from RMB 2,001,906,000 in the prior year[4] - Excluding special items, the net profit attributable to the company's owners was RMB 2,066,668,000, an increase of 4.2% compared to RMB 1,982,432,000 in the previous year[4] - The basic earnings per share for the year was RMB 0.46, up from RMB 0.44 in the previous year[6] - Total comprehensive income for the year was RMB 2,264,712,000, compared to RMB 2,119,784,000 in the previous year[6] - The group reported a total segment profit of RMB 2,304,781,000 for the year ended December 31, 2024, compared to RMB 2,166,194,000 in the previous year, reflecting an increase of 6.4%[14][15] - The company achieved a gross profit of RMB 6,580,631,000, a decrease of 0.9% compared to the previous year[66] Dividends and Shareholder Returns - The company proposed a final dividend of RMB 0.1235 per share, compared to RMB 0.0943 per share in the previous year, pending shareholder approval[3] - The total dividends declared for the year amounted to RMB 851,052,000, an increase of 22.2% from RMB 696,565,000 in 2023[39] - The proposed final dividend for the year ending December 31, 2024, is RMB 0.1235 per share, totaling RMB 564,473,092, compared to RMB 431,010,628 for the previous year[97] - The final dividend will be subject to shareholder approval at the upcoming annual general meeting scheduled for May 27, 2025[97] Assets and Liabilities - The company's total assets amounted to RMB 28,679,345,000, an increase from RMB 26,088,190,000 in the previous year[8] - The company's cash and bank balances rose to RMB 7,780,310,000 from RMB 6,988,731,000 in the previous year[8] - The company’s non-current liabilities increased significantly to RMB 3,337,779,000 from RMB 2,095,485,000 in the previous year[8] - Total liabilities as of December 31, 2024, were RMB 9,418,283 thousand, a decrease from RMB 9,677,526 thousand in 2023[18] - The total accounts payable was RMB 4,473,851,000, a slight decrease from RMB 4,546,147,000 in 2023[51] Research and Development - Research and development expenses increased to RMB 625,233,000 from RMB 592,850,000 in the previous year[5] - Research and development expenses totaled approximately RMB 625,233,000, accounting for 4.8% of the group's revenue, compared to 4.5% in 2023[57] - The group acquired 150 new product registrations and obtained 127 new patents during the year[55] Market Segments and Revenue Sources - The medical device segment generated revenue of RMB 6,512,192,000, accounting for 49.8% of total revenue, while the orthopedic products segment contributed RMB 1,439,446,000, representing 11%[14] - Sales of medical device products amounted to RMB 6,296,502 thousand, down 6.43% from RMB 6,727,859 thousand in the previous year[22] - Orthopedic product sales increased by 13.23% to RMB 1,439,446 thousand from RMB 1,271,203 thousand[22] - Revenue from blood management products decreased by 15.77% to RMB 876,777 thousand compared to RMB 1,041,994 thousand in 2023[22] - The pharmaceutical packaging business achieved revenue of approximately RMB 2,278,608,000, representing a growth of 12.6% year-on-year[56] Employee and Operational Metrics - The company employed a total of 12,719 employees as of December 31, 2024, an increase from 12,519 in the previous year[63] - The total employee costs amounted to RMB 2,431,338,000, up from RMB 2,209,253,000, reflecting an increase of 10.0%[37] Corporate Governance and Compliance - The company has confirmed the independence of its non-executive directors in accordance with the listing rules[89] - The audit committee has reviewed the audited consolidated financial statements for the year and found them to comply with applicable accounting standards[88] - The company has maintained high standards of corporate governance throughout the year, adhering to the corporate governance code[91] Future Plans and Investments - The group plans to continue expanding its product lines and market presence, particularly in the medical device and blood management sectors, to drive future growth[12] - The company plans to continue expanding production facilities and improving production processes to meet future market demand[58] - The group plans to invest approximately RMB 250,000,000 in the new pre-filled syringe and automatic injection pen production lines, expected to commence production in 2026[72] - The group plans to invest RMB 770,000,000 in the Songyuan Health Medical Industry Fund, accounting for 38.5%, with a cumulative investment of RMB 308,000,000[72] Financial Management and Taxation - Current corporate income tax expense increased to RMB 497,733,000, up 23.5% from RMB 403,063,000 in the previous year[32] - The company has a cumulative tax provision of RMB 31,180,000 related to product liability claims, a decrease from RMB 34,962,000 in the previous year[29] - The company’s effective tax rate remains at 15% for certain subsidiaries recognized as high-tech enterprises[33] Miscellaneous - The company recorded a net gain of RMB 4,474,000 from litigation, a significant decrease from RMB 28,548,000 in the previous year[29] - The company received government subsidies amounting to RMB 59,563,000, down from RMB 79,142,000 in the previous year[27] - The company will suspend the transfer of H shares from June 4, 2025, to June 10, 2025, to determine the entitlement to the proposed final dividend[96] - The annual report for the year ending December 31, 2024, is expected to be distributed to shareholders around April 30, 2025[99]
威高股份(01066) - 2024 - 年度业绩